Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in Histiocytic Disorders
NCT06153173Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Feb 2024
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in Langerhans cell histiocytosis (LCH), juvenile xanthogranuloma (JXG), Rosai-Dorfman disease (RDD), histiocytic disorder, sponsored by Cincinnati Children's Hospital Medical Center. Started Feb 2024; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
Langerhans cell histiocytosis (LCH)juvenile xanthogranuloma (JXG)Rosai-Dorfman disease (RDD)histiocytic disorder
Beyond the preview
Go deeper on NCT06153173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153173.